Short answer
Spyre Therapeutics, Inc. (SYRE) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$69M
- −54.1% YoY
- EPS (diluted)
- −$0.74
Source: XBRL data from the Spyre Therapeutics, Inc. (SYRE) Q1 2026 10-Q on SEC EDGAR. USD.
Spyre Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- April 2026 offering: 7,475,000 common shares raised approximately $463 million, creating dilution risk
- Cash, equivalents, and marketable securities totaled $741.5 million at March 31, 2026, but additional capital remains necessary
- Engineered-antibody patent landscape remains highly dynamic, increasing infringement and development-interference risk
- Competitors may offer safer, more effective, cheaper, or more convenient therapies, reducing Spyre’s commercial opportunity
- Expanding AI use creates operational, regulatory, legal, and ethical exposure affecting reputation and results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Spyre Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.